Information Provided By: 
Fly News Breaks for June 21, 2019
CHRS
Jun 21, 2019 | 06:20 EDT
After hosting a meeting with management, Barclays analyst Balaji Prasad says Coherus Biosciences is in "a league of its own, having cracked the commercial code." The analyst now has greater confidence in his projected 22% annual Udenyca sales growth through 2023. He expects Udenyca to reach $400M-plus in 2023 and reiterates an Overweight rating on Coherus shares with a $30 price target. The company's additional pipeline opportunities are also underappreciated, Prasad tells investors in a research note.
News For CHRS From the Last 2 Days
There are no results for your query CHRS
